ProKidney Corp.
Josh Hurt, CPIM, CSCP, currently serves as Purchasing Manager at ProKidney Corp. since July 2023. Previously, Josh held the position of Purchasing Manager at Jowat Adhesives from October 2017 to March 2023, and also worked as a Purchasing Agent there. Prior to that, Josh was a Senior Materials Analyst at RFMD from August 2000 to October 2017 and started a career in market services at ConvaTec from March 1997 to August 2000. Josh's education includes attendance at High Point University from 1995 to 1996.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.